ISPOR's Value Assessment Stakeholder Conference showed its Special Task Force still reaching for clarification around the subject, writes Ansis Helmanis.
Ansis Helmanis
Advertisement
Ansis Helmanis is a former FDA official and founder of RegLink Associates.
Articles by Ansis Helmanis
Harvey Bale, Jr., MD, former Director-General, IFPMA
Jane Henney, MD, Former FDA Commissioner
Advertisement
Latest Updated Articles
IP: Securing a Global Consensus—Can Industry Do It Again?Published: October 1st 2011 | Updated:
Jane Henney: Lessons from the FDA Front LinePublished: October 1st 2011 | Updated:
- ISPOR Task Force Grapples with Value Questions
Published: September 28th 2016 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Targeting CCR5 Receptors
2
Merck to Acquire Cidara for $9.2 Billion
3
Invictus Pharmacy Becomes First US Pharmacy to Accept Cryptocurrency for Prescriptions
4
Komzifti Gains FDA Approval, Giving Kura Oncology and Kyowa Kirin a Key Strategic Win in NPM1-Mutated AML
5
